BridgeBio (BBOT) news

Encaleret increased bone turnover and improved participant-reported symptoms in the phase 3 Calibrate trial in ADH1

BridgeBio Pharma’s Calcilytix Therapeutics recently announced topline results from its Phase 3 CALIBRATE trial of encaleret, an oral therapy under development for individuals with autosomal dominant hypocalcemia type 1 . The trial demonstrated that encaleret increased bone turnover and improved…

BridgEBio announces FDA acceptance & priority review of NDA for

BBP-418 demonstrates potential to be disease modifying therapy, restoring cardiac and disease markers to unaffected levels

BridgeBio Pharma has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for BBP-418, an oral small molecule therapy for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9), a rare, progressive neuromuscular disorder caused by mutations in the FKRP gene. The NDA…

BridgEBio: Attriby cuts Diretic intensification risk 43%

BridgeBio Pharma, Inc. (Nasdaq: BBIO) has reported that its drug Attruby (acoramidis) is associated with 43% reduction in outpatient diuretic intensification compared to tafamidis, according to a real-world study. This finding is part of a broader set of data demonstrating the clinical benefits of…

Bridgebio Oncology Therapeutics Inc: Leerink partners cuts target price to $27 from $39

Leerink Partners has adjusted its price target for BridgeBio Oncology Therapeutics Inc (NASDAQ:BBOT), reducing it to $27 from a previous $39, according to recent analyst activity. This move reflects a reassessment of the company’s outlook, potentially influenced by evolving dynamics in its oncology…